Code is covered without prior authorization (high confidence)
Medicare Pricing
Work RVU
2.03
Facility
$122.92
Non-Facility
$213.77
Documentation Required
Documentation that the chlorhexidine-impregnated dressing used is FDA-cleared with a label specifying the clinical indication for reducing catheter-related bloodstream infection (if claiming benefit for CRBSI prevention).
Clinical documentation of wound type, wound healing intention (primary vs secondary), contamination classification (clean, clean-contaminated, contaminated), and rationale for choosing a specific dressing (e.g., high-exudate wound requiring alginate, painful debridement where EMLA is applied, palliation of fungating wound symptoms).
For malignant wound cultures: documentation of signs/symptoms of infection (e.g., systemic signs, purulence, spreading cellulitis) to justify wound swabbing and microbiological culture; routine swabbing without signs of infection is discouraged.
Key Coverage Criteria
Dressings over a percutaneous catheter or tube (e.g., intravascular, epidural, nephrotomy, etc.) are covered as long as the catheter or tube remains in place and after removal until the wound heals.
CPT codes covered if selection criteria are met: 16020, 16025, 16030, 96574, 97597, 97598, 97602.
HCPCS codes covered if selection criteria are met include (non-exhaustive as listed in policy): A4450, A4452, A4649, A6025, A6154, A6196–A6199 (alginate), A6200–A6205 (composite), A6206–A6208 (contact layer), A6209–A6215 (foam), A6216–A6221 (gauze nonimpregnated), A6222–A6233 (gauze impregnated), A6234–A6241 (hydrocolloid), A6242–A6248 (hydrogel), A6251–A6256 (specialty absorptive), A6257–A6259 (transparent film), A6261 (wound filler gel/paste), A6262 (wound filler dry form), A6266 (gauze impreg [...]
ICD-10 codes explicitly listed as covered if selection criteria are met include: pressure ulcer stage III or IV (L89.003–L89.094 and multiple stage III/IV variants listed), non-pressure chronic ulcer stage III or IV (L97.100–L97.929), burns and corrosion of various body regions second or third degree (T20.20x+–T25.* series second/third degree ranges as listed), persistent postprocedural fistula (T81.83x+), open wounds (numerous codes listed/not listed due to specificity).
Chlorhexidine-impregnated dressings to protect the insertion site of short-term, nontunneled central venous catheters (CVCs) in adults for reduction of catheter colonization and catheter-related bloodstream infection (CRBSI) — supported by RCT meta-analysis and recommended by the CDC when the dressing has an FDA-cleared label specifying this clinical indication.
Use of 5% eutectic mixture of local anesthetics (EMLA; lidocaine-prilocaine cream) to reduce pain associated with debridement of venous leg ulcers (statistically significant reduction in debridement pain scores reported).
1 Active Policy
AETNA-CPB-0526 — Surgical Dressings (Wound Care Supplies)
Ask Verity about documentation requirements, denial risks, or coverage in your state.
When using advanced or costly dressings/technologies (e.g., NPWT, DACC-coated dressings, oxygen-diffusion dressings), clinical notes should document prior treatments, medical necessity, and expected benefit given the limited/variable evidence base.
Reference to applicable Local Coverage Determinations and DME MAC policy (e.g., LCD L11471, Noridian L33831) and adherence to their specific documentation or billing requirements when applicable.
For traditional plans: physician prescription required and supply by home care agency must be in conjunction with covered home health care services, or dispensed/used by participating provider in conjunction with treatment — documentation of prescription and dispensing context required.